Regencell Bioscience Holdings Limited news

Class action alleges vulnerability to market manipulation, share price volatility, and heightened risk of regulatory scrutiny and enforcement action, exposing investors to significant financial risk.

Company is subject to a securities class action lawsuit alleging false/misleading statements regarding market manipulation vulnerability, regulatory risks, and investor financial harm during the Class Period (October 28, 2024 - October 31, 2025).

The company is the subject of a federal securities class action lawsuit alleging fraud and misleading statements. A DOJ investigation into trading in the company's shares was disclosed, resulting in an 18.56% stock price decline. The company faces potential significant legal costs, fines, penalties, and settlement costs.

Company is subject to a securities class action lawsuit alleging false/misleading statements about vulnerability to market manipulation, resulting volatility, and regulatory risks. Investors with losses exceeding $100K are being encouraged to join the lawsuit.

Company faces class action lawsuit for alleged securities fraud and material misstatements. Stock experienced extreme unexplained volatility (48,650% increase followed by collapse), company has no approved products or revenue, and is under DOJ investigation for potential market manipulation. These factors indicate significant legal, financial, and reputational risks.

Company is subject to securities class action lawsuit alleging false/misleading statements, vulnerability to market manipulation, and regulatory/governmental scrutiny that caused investor losses.

The company is the subject of a securities fraud class action lawsuit alleging materially false and misleading statements, vulnerability to market manipulation, and failure to disclose significant financial risks to investors. These allegations represent serious legal and reputational harm.

The company faces a federal securities class action lawsuit alleging fraud through false and misleading statements about market manipulation vulnerability and regulatory risks. A DOJ investigation was disclosed, resulting in an 18.56% stock price decline and significant investor losses. The company expects substantial legal costs and potential fines or settlement payments.

The company is the subject of a securities class action lawsuit alleging false and misleading statements, failure to disclose market manipulation vulnerabilities, and exposure of investors to significant financial risk. These allegations indicate serious corporate governance and disclosure issues that resulted in investor damages.

Company is subject to a securities class action lawsuit alleging false and misleading statements regarding vulnerability to market manipulation, regulatory risks, and investor financial harm during the Class Period (October 28, 2024 - October 31, 2025).

The company is facing a DOJ investigation into trading practices, disclosed material vulnerabilities to market manipulation, and experienced an 18.56% stock price decline following the disclosure. Additionally, a securities fraud class action lawsuit has been filed alleging materially false statements and failure to disclose material adverse facts about business operations and regulatory risks.

Company is defendant in securities class action lawsuit, though specific allegations are not detailed in the provided excerpt.

Company is subject to a securities class action lawsuit alleging false/misleading statements about vulnerability to market manipulation, regulatory risks, and resulting investor financial harm during the Class Period (October 28, 2024 - October 31, 2025).

Decreased 12.61% last week with no specific catalyst mentioned

The company is the subject of a class action lawsuit alleging false and misleading statements, market manipulation vulnerability, and regulatory risks. These allegations indicate serious compliance and operational issues that have resulted in investor losses.

Company is subject to securities class action lawsuit alleging false/misleading statements, vulnerability to market manipulation, and regulatory/governmental scrutiny. Investors suffered damages when true details entered the market.

The company is the subject of a securities class action lawsuit alleging false and misleading statements, failure to disclose market manipulation vulnerabilities, and exposure to regulatory and governmental scrutiny. These allegations indicate serious corporate governance and disclosure issues that resulted in investor losses.

Company is subject to class action lawsuit alleging materially false and misleading statements regarding vulnerability to market manipulation during October 2024 to October 2025 period.

Company is subject to securities class action lawsuit alleging false/misleading statements regarding vulnerability to market manipulation, share price volatility, and regulatory/governmental scrutiny, resulting in investor financial losses.

Company is subject to securities fraud allegations involving market manipulation vulnerability, undisclosed regulatory risks, and materially misleading statements about business operations and prospects.

The company is the subject of a securities class action lawsuit alleging false and misleading statements about market manipulation vulnerabilities, share price volatility, and regulatory risks. Investors who purchased during the class period may have suffered damages.

The company is the subject of a class action lawsuit alleging false and misleading statements, failure to disclose material adverse facts, vulnerability to market manipulation, and exposure to regulatory and enforcement action. These allegations indicate serious compliance and governance issues that resulted in investor losses.

Company is subject to a securities class action lawsuit alleging false/misleading statements regarding market manipulation vulnerability, regulatory risks, and investor financial harm during the Class Period (October 28, 2024 - October 31, 2025).

The company is the subject of a class action lawsuit alleging material misstatements and omissions regarding market manipulation vulnerabilities and regulatory risks. A DOJ investigation into trading practices was disclosed, resulting in an 18.56% stock price decline and significant legal and financial exposure.

Company is subject to securities class action lawsuit alleging false and misleading statements regarding market manipulation vulnerabilities, regulatory risks, and failure to disclose material information that caused investor damages.

The company is the subject of a class action lawsuit alleging false and misleading statements, failure to disclose material adverse facts, vulnerability to market manipulation, and exposure to regulatory and enforcement action. These allegations indicate serious compliance and governance issues that resulted in investor losses.

The company is the subject of a securities class action lawsuit alleging material misstatements and non-disclosure of market manipulation vulnerabilities and associated financial risks to investors, indicating serious legal and reputational concerns.

Increased 15.01% after announcing a sales agreement for up to $500 million of shares under an at-the-market offering program

Company has been operating since 2014 with no saleable products, no revenue from product sales, and operates in high-risk early-stage biotech sector. The massive stock price increase is viewed as unsustainable and driven by speculation rather than fundamentals.

Company is under DOJ investigation for trading practices, disclosed significant legal costs and potential fines/penalties, and experienced an 18.56% stock price decline on the news.

Pre-commercial biotech with $12.8B market cap despite minimal clinical catalysts, no revenue, consistent unprofitability, and company-stated substantial doubt about remaining in business. Stock performance driven by market dynamics rather than fundamentals, making it an extraordinarily risky investment.

Company is subject to a securities class action lawsuit with a June 23 deadline, indicating alleged investor harm and regulatory concerns.

The company is subject to a securities class action lawsuit with a deadline alert issued, indicating alleged securities violations and investor losses, though specific details are not provided in the excerpt.

Company is defendant in a securities class action lawsuit with a specific deadline for investors with losses exceeding $100,000, indicating material investor losses from alleged securities violations.

Company is defendant in securities class action lawsuit with investors encouraged to secure counsel before the deadline, indicating alleged securities violations.

Company is subject to class action lawsuit filed by Bragar Eagel & Squire, P.C., indicating alleged investor losses and potential securities violations, though specific allegations are not detailed in the provided excerpt.

Subject of a class action lawsuit filed by Rosen Law Firm, indicating alleged securities violations, though specific details are not provided in the article excerpt.